Preventing invasive salmonellosis in children through vaccination

References

• Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet. 2015;385:1136–1145.
   PubMed Web of Science ®Google Scholar
• Gordon MA. Invasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosis. Curr Opin Infect Dis. 2011;24:484–489.
   PubMed Web of Science ®Google Scholar
• Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med. 2002;347:1770–1782.
   PubMed Web of Science ®Google Scholar
• Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2:e570–580.
   PubMed Web of Science ®Google Scholar
• Brooks WA, Hossain A, Goswami D, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005;11:326–329.
   PubMed Web of Science ®Google Scholar
• De Roeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med. 2007;357:1069–1071.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SS, Dash U. A sudden rise in occurrence of Salmonella paratyphi A infection in Rourkela, Orissa. Indian J Med Microbiol. 2007;25:78–79.
   PubMedGoogle Scholar
• Pandit A, Arjyal A, Paudyal B, et al. A patient with paratyphoid A fever: an emerging problem in Asia and not always a benign disease. J Travel Med. 2008;15:364–365.
   PubMed Web of Science ®Google Scholar
• Maskey AP, Basnyat B, Thwaites GE, et al. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993–2003. Trans R Soc Trop Med Hyg. 2008;102:91–95.
   PubMed Web of Science ®Google Scholar
• Kothari A, Pruthi A, Chugh TD. The burden of enteric fever. J Infect Dev Ctries. 2008;2:253–259.
   PubMed Web of Science ®Google Scholar
• Naheed A, Ram PK, Brooks WA, et al. Burden of typhoid and paratyphoid fever in a densely populated urban community, Dhaka, Bangladesh. Int J Infect Dis. 2010;14:e93–e99.
   PubMed Web of Science ®Google Scholar
• Meltzer E, Schwartz E. Enteric fever: a travel medicine oriented view. Curr Opin Infect Dis. 2010;23:432–437.
   PubMed Web of Science ®Google Scholar
• Arndt MB, Mosites EM, Tian M, et al. Estimating the burden of paratyphoid a in Asia and Africa. PLoS Negl Trop Dis. 2014;8:e2925.
   PubMed Web of Science ®Google Scholar
• Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:417–432.
   PubMed Web of Science ®Google Scholar
• Nielsen MV, Sarpong N, Krumkamp R, et al. Incidence and characteristics of bacteremia among children in rural Ghana. PLoS One. 2012;7:e44063.
   PubMed Web of Science ®Google Scholar
• Tabu C, Breiman RF, Ochieng B, et al. Differing burden and epidemiology of non-Typhi Salmonella bacteremia in rural and urban Kenya, 2006–2009. PLoS One. 2012;7:e31237.
   PubMed Web of Science ®Google Scholar
• Phoba MF, De Boeck H, Ifeka BB, et al. Epidemic increase in Salmonella bloodstream infection in children, Bwamanda, the Democratic Republic of Congo. Eur J Clin Microbiol Infect Dis. 2014;33:79–87.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Typhoid vaccines. Pos Pap Wkly Epidemiol Rec. 2008;83:49–60.
   PubMedGoogle Scholar
• Date KA, Bentsi-Enchill AD, Fox KK, et al. Typhoid fever surveillance and vaccine use – South-East Asia and Western Pacific regions, 2009–2013. Morb Mortal Wkly Rep. 2014;63:855–860.
   PubMed Web of Science ®Google Scholar
• Slayton RB, Date KA, Mintz ED. Vaccination for typhoid fever in sub-Saharan Africa. Hum Vaccine Immunother. 2013;9:903–906.
   PubMed Web of Science ®Google Scholar
• Date KA, Bentsi-Enchill A, Marks F, et al. Typhoid fever vaccination strategies. Vaccine. 2015;33(Suppl. 3):C55–C61.
   PubMed Web of Science ®Google Scholar
• Kariuki S, Gordon MA, Feasey N, et al. Antimicrobial resistance and management of invasive Salmonella disease. Vaccine. 2015;33(Suppl. 3):21–29.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Field and laboratory studies with typhoid vaccines: a preliminary report: Yugoslav Typhoid Commission. Bull World Health Organ. 1957;16:897–910.
   PubMedGoogle Scholar
• Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2000;2:CD001261.
   PubMedGoogle Scholar
• Stuhl L, Benda R, Frey N. A controlled field trial of the effectiveness of acetone- dried and inactivated and heat-phenolinactivated typhoid vaccines in Yugoslavia. Bull World Health Organ. 1964;30:623–630.
   PubMedGoogle Scholar
• Ashcroft MT, Ritchie JM, Nicholson CC. Controlled field trial in British Guiana school children of heat-killed-phenolized and acetone-killed lyophilized typhoid vaccines. Am J Hyg. 1964;79:196–206.
   PubMed Web of Science ®Google Scholar
• Hejfec LB, Salmin LV, Lejtman MZ, et al. A controlled field trial and laboratory study of five typhoid vaccines in the USSR. Bull World Health Organ. 1966;34:321–339.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated recommendations for the use of typhoid vaccine - Advisory Committee on Immunization Practices, United States, 2015; [ cited 2016 Jan 7]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a4.htm
   Google Scholar
• Indian Academy of Pediatrics. Recommended immunization schedule for children aged 0 through 18 years – India, 2013 and updates on immunization. Indian Pediatr. 2013;50:1095–1108.
   PubMed Web of Science ®Google Scholar
• Wong KH, Feeley JC, Pittman M, et al. Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol. J Infect Dis. 1974;129:501–506.
   PubMedGoogle Scholar
• Hessel L, Debois H, Fletcher M, et al. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis. 1999;18:609–620.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Inter Med. 1995;155:2293–2299.
   PubMed Web of Science ®Google Scholar
• Szu SC, Taylor DN, Trofa AC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun. 1994;62:4440–4444.
   PubMed Web of Science ®Google Scholar
• Cordero-Yap L, Rivera RG, Dispo AP, et al. Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2–5 years. BioDrugs. 2001;15(Suppl. 1):27.
   PubMed Web of Science ®Google Scholar
• Ramkissoon A, Jugnundan P. Reactogenicity and immunogenicity of a single dose of a typhoid Vi polysaccharide vaccine in adolescents. BioDrugs. 2001;15(Suppl. 1):21–26.
   PubMed Web of Science ®Google Scholar
• Pelser HH. Reactogenicity and immunogenicity of a single dose of typhoid Vi polysaccharide vaccine in children aged between 4 and 14 years. BioDrugs. 2001;15(Suppl. 1):13–19.
   PubMed Web of Science ®Google Scholar
• Fraser A, Paul M, Goldberg E, et al. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine. 2007;25:7848–7857.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Koornhof HJ, Robbins JB, et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996;14:435–438.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nature Rev Immunol. 2009;9:213–220.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Gilbertson IT, Koornhoff HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987;2:1165–1169.
   PubMed Web of Science ®Google Scholar
• Khan MI, Soofi SB, Ochiai RL, et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine. 2012;30:5389–5395.
   PubMed Web of Science ®Google Scholar
• Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009;361:335–344.
   PubMed Web of Science ®Google Scholar
• Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ. 2001;79:625–631.
   PubMed Web of Science ®Google Scholar
• Cook J, Jeuland M, Whittington D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008;26:6305–6316.
   PubMed Web of Science ®Google Scholar
• Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine. 1990;8:81–84.
   PubMed Web of Science ®Google Scholar
• Baker S, Sarwar Y, Aziz H, et al. Detection of Vi-negative Salmonella enterica serovar typhi in the peripheral blood of patients with typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol. 2005;43:4418–4425.
   PubMed Web of Science ®Google Scholar
• Wain J, House D, Zafar A, et al. Vi antigen expression in Salmonella enterica serovar typhi clinical isolates from Pakistan. J Clin Microbiol. 2005;43:1158–1165.
   PubMed Web of Science ®Google Scholar
• Zhou WZ, Koo HW, Wang XY, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. Pediatr Infect Dis J. 2007;26:1001–1005.
   PubMed Web of Science ®Google Scholar
• Pulickal AS, Pollard AJ. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype? Expert Rev Vaccines. 2007;6:293–295.
   PubMed Web of Science ®Google Scholar
• Mathew JL. Conjugate typhoid vaccine(s) in the Indian context. Indian Pediatr. 2009;46:182–184.
   PubMed Web of Science ®Google Scholar
• Mohan VK, Varanasi V, Singh A, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402.
   PubMed Web of Science ®Google Scholar
• Wahdan MH, Sippel JE, Mikhail IA, et al. Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2. Bull World Health Organ. 1975;52:69–73.
   PubMed Web of Science ®Google Scholar
• Wahdan MH, Sérié C, Cerisier Y, et al. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982;145:292–295.
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Abrego P, et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999;17(Suppl. 2):22–27.
   Web of Science ®Google Scholar
• Black RE, Levine MM, Young CR, et al. Immunogenicity of Ty2la attenuated Salmonella typhi given with sodium bicarbonate or in enteric-coated capsules. J Biol Stand. 1983;53:9–14.
   Google Scholar
• Murphy JR, Grez L, Schlesinger L, et al. Immunogenicity of Salmonella typhi Ty2la vaccine for young children. Infect Immun. 1991;59:4291–4293.
   PubMed Web of Science ®Google Scholar
• Ferreccio C, Levine MM, Rodriguez H, et al. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in endemic area. J Infect Dis. 1989;159:766–769.
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;1:1049–1052.
   PubMed Web of Science ®Google Scholar
• Gilman RH, Hornick RB, Woodward WE, et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine. J Infect Dis. 1977;136:717–723.
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Vanprapar N, Thisyakorn U, et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun. 1993;61:1149–1151.
   PubMed Web of Science ®Google Scholar
• Bhuiyan TR, Choudhury FK, Khanam F, et al. Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh. Vaccine. 2014;32:1055–1060.
   PubMed Web of Science ®Google Scholar
• El Edelbi R, Eksborg S, Lindemalm S. In situ coating makes it easier for children to swallow and tolerate tablets and capsules. Acta Paediatr. 2015;104:956–961.
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Black RE, et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis. 2007;45(Suppl. 1):24–28.
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991;338:1055–1059.
   PubMed Web of Science ®Google Scholar
• Wahid R, Simon R, Zafar SJ, et al. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar paratyphi A and S. paratyphi B in humans. Clin Vaccine Immunol. 2012;19:825–834.
   PubMed Web of Science ®Google Scholar
• Pakkanen SH, Kantele JM, Kantele A. Cross-reactive gut-directed immune response against Salmonella enterica serovar paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine. 2012;30:6047–6053.
   PubMed Web of Science ®Google Scholar
• Kossaczka Z, Lin FY, Ho VA, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun. 1999;67:5806–5810.
   PubMed Web of Science ®Google Scholar
• Anwar E, Goldberg E, Fraser A, et al. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2014;1:CD001261.
   PubMed Web of Science ®Google Scholar
• Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344:1263–1269.
   PubMed Web of Science ®Google Scholar
• Thiem VD, Lin FY, Canh Do G, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol. 2011;18:730–735.
   PubMed Web of Science ®Google Scholar
• Bhutta ZA, Capeding MR, Bavdekar A, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014;14:119–129.
   PubMed Web of Science ®Google Scholar
• Park SE, Marks F. A conjugate vaccine against typhoid fever. Lancet Infect Dis. 2014;14:90–91.
   PubMed Web of Science ®Google Scholar
• Szu SC. Development of Vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines. 2013;12:1273–1286.
   PubMed Web of Science ®Google Scholar
• Zuñiga J, Lillo L, Shin JJ, et al. Salmonella enterica serovar typhi O:1,9,12 polysaccharide-protein conjugate as a diagnostic tool for typhoid fever. J Clin Microbiol. 2005;43:4545–4550.
   PubMed Web of Science ®Google Scholar
• Ali A, An SJ, Cui C, et al. Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid. Hum Vaccin Immunother. 2014;10:1494–1498.
   PubMed Web of Science ®Google Scholar
• Konadu EY, Lin FY, Hó VA, et al. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun. 2000;68:1529–1534.
   PubMed Web of Science ®Google Scholar
• Sahastrabuddhe S, Carbis R, Wierzba TF, et al. Increasing rates of Salmonella paratyphi A and the current status of its vaccine development. Expert Rev Vaccines. 2013;12:1021–1031.
   PubMed Web of Science ®Google Scholar
• Micoli F, Rondini S, Gavini M, et al. O:2-CRM(197) conjugates against Salmonella paratyphi A. PLoS One. 2012;7:e47039.
   PubMed Web of Science ®Google Scholar
• Simon R, Wang JY, Boyd MA, et al. Sustained protection in mice immunized with fractional doses of Salmonella enteritidis core and O polysaccharide-flagellin glycoconjugates. PLoS One. 2013;8:e64680.
   PubMed Web of Science ®Google Scholar
• Rondini S, Micoli F, Lanzilao L, et al. Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium. Infect Immun. 2015;83:996–1007.
   PubMed Web of Science ®Google Scholar
• Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine. 1996;14:19–24.
   PubMed Web of Science ®Google Scholar
• Hohmann EL, Oletta CA, Killeen KP, et al. phoP/phoQdeleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis. 1996;173:1408–1414.
   PubMed Web of Science ®Google Scholar
• Tran TH, Nguyen TD, Nguyen TT, et al. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One. 2010;5:e11778.
   PubMed Web of Science ®Google Scholar
• Lyon CE, Sadigh KS, Carmolli MP, et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10 (10)colony-forming units. Vaccine. 2010;28:3602–3608.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, McKenzie R, O’Neill JP, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine. 2006;24:116–123.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Hone DM, Losonsky GA, et al. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine. 1992;10:443–446.
   PubMed Web of Science ®Google Scholar
• Johnson K, Charles I, Dougan G, et al. The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol. 1991;5:401–407.
   PubMed Web of Science ®Google Scholar
• Salerno-Goncalves R, Wyant TL, Pasetti MF, et al. Concomitant induction of CD4þ and CD8þ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. J Immunol. 2003;170:2734–2741.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Wasserman SS, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun. 2000;68:1196–1201.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Pasetti MF, Sztein MB, et al. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis. 2004;190:565–570.
   PubMed Web of Science ®Google Scholar
• Gat O, Galen JE, Tennant S, et al. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl Trop Dis. 2011;5:e1373.
   PubMed Web of Science ®Google Scholar
• Roland KL, Tinge SA, Kochi SK, et al. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar paratyphi A enteric fever vaccine candidates. Vaccine. 2010;28:3679–3687.
   PubMed Web of Science ®Google Scholar
• Tennat SM, Levine MM. Live attenuated vaccines for invasive Salmonella infections. Vaccine. 2015;33(Suppl. 3):C38–C41.
   Google Scholar
• Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet. 1994;344:362–366.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiol. 2015;10:1599–1607.
   PubMed Web of Science ®Google Scholar
• Dong BQ, Yang J, Wang XY, et al. Trends and disease burden of enteric fever in Guangxi province, China, 1994–2004. Bull World Health Organ. 2010;88:689–696.
   PubMed Web of Science ®Google Scholar
• Waddington CS, Darton TC, Pollard AJ. The challenge of enteric fever. J Infect. 2014;68:S38–S50.
   PubMed Web of Science ®Google Scholar
• Szu SC, Klugman KP, Hunt S. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine. 2014;32:2359–2363.
   PubMed Web of Science ®Google Scholar
• Watson CH, Edmunds WJ. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination. Vaccine. 2015;33(Suppl 3):C42–54.
   PubMed Web of Science ®Google Scholar
• Wahid R, Pasetti MF, Maciel M Jr, et al. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin Immunol. 2011;138:187–200.
   PubMed Web of Science ®Google Scholar
• Forrest BD, LaBrooy JT, Beyer L, et al. The human humoral immune response to Salmonella typhi Ty21a. J Infect Dis. 1991;163:336–345.
   PubMed Web of Science ®Google Scholar
• Tagliabue A, Villa L, De Magistris MT, et al. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol. 1986;137:1504–1510.
   PubMed Web of Science ®Google Scholar
• Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine. 1990;8:321–326.
   PubMed Web of Science ®Google Scholar